Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Concurrent management of vitiligo and acquired disorders of hyperpigmentation: a comprehensive literature review and current practice gaps.
Int J Dermatol
March 2025
Division of Photobiology and Photomedicine, Department of Dermatology, Henry Ford Health, Detroit, MI, USA.
Few studies discuss the co-management of vitiligo and acquired hyperpigmentation disorders (AHD) such as melasma, erythema dyschromicum perstans, post-inflammatory hyperpigmentation, drug-induced hyperpigmentation, and lichen planus pigmentosus. This review discusses clinical studies examining co-management strategies and identifies current practice gaps. Dermatology Life Quality Index scores are higher in individuals with vitiligo or melasma.
View Article and Find Full Text PDFDisorders of hyperpigmentation and associated thyroid abnormalities: a retrospective cohort study.
Arch Dermatol Res
August 2024
Department of Dermatology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Quality of life in patients with acquired dermal macular hyperpigmentation: a systematic review.
Clin Exp Dermatol
November 2024
Chroma Dermatology, University of Melbourne, Carlton, VIC, Australia.
Article Synopsis
- * A review of existing literature found a lack of systematic studies on how these conditions impact patients' quality of life (QOL), with only seven studies meeting criteria to highlight impairment in QOL due to ADMH.
- * Overall, the studies suggest that ADMH significantly affects QOL, potentially more so than melasma and similar to or less than vitiligo, emphasizing the need for clinicians to consider the psychosocial aspects when managing patients with these conditions.
Erythema dyschromicum perstans-like eruptions induced by epidermal growth factor receptor inhibitors in patients with lung cancer.
Support Care Cancer
May 2024
Department of Dermatology, Stanford University, 450 Broadway St Pav B 4th Fl, Redwood City Palo Alto, CA, 94063, USA.
Introduction: Cutaneous adverse reactions to epidermal growth factor receptor inhibitors (EGFRi) are some of the most common side effects that patients experience. However, cutaneous adverse reactions that cause dyspigmentation in patients have been rarely reported. Erythema dyschromicum perstans (EDP) is a rare pigmentary condition that causes ashy-grey hyperpigmented macules and patches, with a few cases reported from EGFRi in the literature.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!